首页> 美国卫生研究院文献>Critical Care >Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
【2h】

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis

机译:重度念珠菌血症和其他形式的侵袭性念珠菌病患者中阿尼芬净与氟康唑的比较:支持2009 IDSA念珠菌治疗指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionDuring the past decade, the incidence of Candida infections in hospitalized patients has increased, with fluconazole being the most commonly prescribed systemic antifungal agent for these infections. However, the 2009 Infectious Diseases Society of America (IDSA) candidiasis guidelines recommend an echinocandin for the treatment of candidemia/invasive candidiasis in patients who are considered to be "moderately severe or severely" ill. To validate these guidelines, clinical trial data were reviewed.
机译:简介在过去的十年中,住院患者念珠菌感染的发生率有所增加,氟康唑是这些感染最常用的全身性抗真菌药。但是,《 2009年美国传染病学会(IDSA)念珠菌病指南》建议使用棘皮菌素治疗被认为是“中度重度或重度”疾病的患者的念珠菌血症/侵袭性念珠菌病。为了验证这些指南,对临床试验数据进行了审查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号